全文获取类型
收费全文 | 4489篇 |
免费 | 276篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 82篇 |
妇产科学 | 83篇 |
基础医学 | 588篇 |
口腔科学 | 84篇 |
临床医学 | 305篇 |
内科学 | 1281篇 |
皮肤病学 | 48篇 |
神经病学 | 371篇 |
特种医学 | 189篇 |
外科学 | 638篇 |
综合类 | 45篇 |
预防医学 | 367篇 |
眼科学 | 68篇 |
药学 | 217篇 |
中国医学 | 3篇 |
肿瘤学 | 373篇 |
出版年
2023年 | 18篇 |
2022年 | 23篇 |
2021年 | 60篇 |
2020年 | 32篇 |
2019年 | 70篇 |
2018年 | 60篇 |
2017年 | 72篇 |
2016年 | 65篇 |
2015年 | 61篇 |
2014年 | 136篇 |
2013年 | 157篇 |
2012年 | 271篇 |
2011年 | 239篇 |
2010年 | 147篇 |
2009年 | 129篇 |
2008年 | 195篇 |
2007年 | 218篇 |
2006年 | 237篇 |
2005年 | 228篇 |
2004年 | 197篇 |
2003年 | 222篇 |
2002年 | 254篇 |
2001年 | 217篇 |
2000年 | 233篇 |
1999年 | 165篇 |
1998年 | 64篇 |
1997年 | 31篇 |
1996年 | 42篇 |
1995年 | 28篇 |
1994年 | 40篇 |
1993年 | 32篇 |
1992年 | 86篇 |
1991年 | 68篇 |
1990年 | 73篇 |
1989年 | 64篇 |
1988年 | 63篇 |
1987年 | 63篇 |
1986年 | 52篇 |
1985年 | 39篇 |
1984年 | 32篇 |
1983年 | 28篇 |
1982年 | 13篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 27篇 |
1978年 | 18篇 |
1977年 | 22篇 |
1975年 | 14篇 |
1973年 | 13篇 |
1972年 | 15篇 |
排序方式: 共有4770条查询结果,搜索用时 15 毫秒
111.
112.
Andrea E. Steuer Justine Raeber Christian Steuer Martina I. Boxler Dario A. Dornbierer Oliver G. Bosch Boris B. Quednow Erich Seifritz Thomas Kraemer 《Drug testing and analysis》2019,11(6):813-823
Gamma‐hydroxybutyrate (GHB) is a short‐chain fatty acid that occurs naturally in the mammalian brain and is prescribed as a medication against narcolepsy or used as a drug of abuse. Particularly, its use as a knock‐out drug in cases of drug‐facilitated crimes is of major importance in forensic toxicology. Because of its rapid metabolism and resulting narrow detection windows (<12 hours in urine), detection of GHB remains challenging. Thus, there is an urgent call for new markers to improve the reliable detection of GHB use. In the framework of a randomized, placebo‐controlled, crossover study in 20 healthy male volunteers, urine samples obtained 4.5 hours post‐administration were submitted to untargeted mass spectrometry [MS, quadrupole time of flight (QTOF)] analysis to identify possible new markers of GHB intake. MS data from four different analytical methods (reversed phase and hydrophilic interaction liquid chromatography; positive and negative electrospray ionization) were filtered for significantly changed features applying univariate and multivariate statistics. From the resulting 42 compounds of interest, 8 were finally identified including conjugates of GHB with carnitine, glutamate, and glycine as well as the endogenous compounds glycolate and succinylcarnitine. While GHB conjugates were only detectable in the GHB, but not in the placebo group, glycolate and succinylcarnitine were present in both groups albeit significantly increased through GHB intake. Untargeted metabolomics proved as a suitable tool for the non‐hypothesis driven identification of new GHB markers. However, more studies on actual concentrations, detection windows, and stability will be necessary to assess the suitability of these markers for routine application. 相似文献
113.
114.
Yvonne P.J. Bosch Raed Al DieriHugo ten Cate Patty J. NelemansSaartje Bloemen Bas de LaatCoenraad Hemker Patrick W. WeerwindJos G. Maessen Baheramsjah Mochtar 《Thrombosis research》2014
Introduction
Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) are susceptible to haemostatic disturbances. Monitoring the haemostatic capacity by conventional clotting tests is challenging.Materials and Methods
Thrombin generation (TG) by Calibrated Automated Thrombography, clotting tests and tissue factor pathway inhibitor (TFPI) measurements were performed to describe the relationship between haemostatic changes and alterations in these tests. Blood samples were collected before, during and after CPB. Furthermore, it was investigated whether TG measured intraoperatively, is associated with increased risk of bleeding postoperatively.Results
TG diminished significantly (p < 0.01) after heparinization in the presence and absence of platelets (37% and 50%) compared to baseline. After the start of CPB, TG elevated and persisted till the end of surgery but remained lower than preoperatively. Activated clotting time increased after heparinization and after the start of bypass compared to baseline (400% and 500%). Anti-FXa activity reduced on the start of CPB compared to the level after heparinization, to almost the baseline value following protamine reversal of heparin. The plasma levels of total and free TFPI elevated 9 and 14 fold during bypass and remained after protamine administration higher than preoperatively. Plasma D-dimer levels reduced (p < 0.01) when bypass started. However, a marked elevation was observed in the following time points. TG in platelet-rich plasma measured after heparinization and after the start of CPB associated (p < 0.05) with postoperative blood loss.Conclusions
TG can be determined during CPB despite the high heparinization level, it reflects the haemostatic capacity better than clotting-based assays and might better predict bleeding when performed intraoperatively. 相似文献115.
116.
Archin NM Vaidya NK Kuruc JD Liberty AL Wiegand A Kearney MF Cohen MS Coffin JM Bosch RJ Gay CL Eron JJ Margolis DM Perelson AS 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(24):9523-9528
HIV type 1 (HIV-1) persists within resting CD4(+) T cells despite antiretroviral therapy (ART). To better understand the kinetics by which resting cell infection (RCI) is established, we developed a mathematical model that accurately predicts (r = 0.65, P = 2.5 × 10(-4)) the initial frequency of RCI measured about 1 year postinfection, based on the time of ART initiation and the dynamic changes in viremia and CD4(+) T cells. In the largest cohort of patients treated during acute seronegative HIV infection (AHI) in whom RCI has been stringently quantified, we found that early ART reduced the generation of latently infected cells. Although RCI declined after the first year of ART in most acutely infected patients, there was a striking absence of decline when initial RCI frequency was less than 0.5 per million. Notably, low-level viremia was observed more frequently as RCI increased. Together these observations suggest that (i) the degree of RCI is directly related to the availability of CD4(+) T cells susceptible to HIV, whether viremia is controlled by the immune response and/or ART; and (ii) that two pools of infected resting CD4(+) T cells exist, namely, less stable cells, observable in patients in whom viremia is not well controlled in early infection, and extremely stable cells that are established despite early ART. These findings reinforce and extend the concept that new approaches will be needed to eradicate HIV infection, and, in particular, highlight the need to target the extremely small but universal, long-lived latent reservoir. 相似文献
117.
Cryoglobulins are immunoglobulins that precipitate in vitro at temperatures less than 37°C and produce organ damage through two main pathways: vascular sludging (hyperviscosity syndrome, mainly in type I cryoglobulinaemia) and immune-mediated mechanisms (principally vasculitis, in mixed cryoglobulinaemia). Cryoglobulinaemia is associated with many illnesses, which can be broadly grouped into infections, autoimmune disorders, and malignancies; the most common cause is infection with hepatitis C virus. Mixed cryoglobulinaemic syndrome is diagnosed when a patient has typical organ involvement (mainly skin, kidney, or peripheral nerve) and circulating cryoglobulins. Cutaneous purpura is the most common manifestation of cryoglobulinaemic vasculitis. The most frequently affected internal organs are the peripheral nerves, kidneys, and joints. The course varies widely and prognosis is influenced by both cryoglobulinaemic damage to vital organs and by comorbidities associated with underlying diseases. More than 90% of cases of cryoglobulinaemia have a known underlying cause; therefore treatment is focused on the cause of the disorder rather than merely symptomatic relief. Studies suggest that both combined or sequential antiviral therapies and targeted biological treatments might be more effective than monotherapy. 相似文献
118.
Ramos-Casals M Sanz I Bosch X Stone JH Khamashta MA 《The American journal of medicine》2012,125(4):327-336
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled trials have shown negative results for rituximab, promising results for epratuzumab, and positive results for belimumab. Despite these negative results, rituximab is the most-used agent in patients who do not respond or are intolerant to standard therapy and those with life-threatening presentations. B-cell-depleting agents should not be used in patients with mild disease and should be tailored according to individual patient characteristics, including ethnicity, organ involvement, and the immunological profile. Forthcoming studies of B-cell-directed strategies, particularly data from investigations of off-label rituximab use and postmarketing studies of belimumab, will provide new insights into the utility of these treatments in the routine management of patients with systemic lupus erythematosus. 相似文献
119.
120.